Filing Details

Accession Number:
0001209191-20-038238
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-22 17:27:10
Reporting Period:
2020-06-19
Accepted Time:
2020-06-22 17:27:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1325879 Aveo Pharmaceuticals Inc. AVEO Pharmaceutical Preparations (2834) 043581650
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1559827 Jr. A. Anthony Florence 5425 Wisconsin Avenue, Suite 800
Chevy Chase MD 20815
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-19 1,428,571 $5.25 3,952,958 No 4 P Indirect See Note 2
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Note 2
Footnotes
  1. On February 19, 2020, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
  2. The Reporting Person is a manager of NEA 15 GP, LLC ("NEA 15 GP"), which is the sole general partner of NEA Partners 15, L.P. ("NEA Partners 15"). NEA Partners 15 is the sole general partner of New Enterprise Associates 15, L. P. ("NEA 15"). NEA 15 is the sole member of Growth Equity Opportunities Fund IV, LLC ("GEO IV"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by GEO IV in which the Reporting Person has no pecuniary interest.